Disease or Syndrome
White House pulls Weldon’s nomination to lead CDC at last minute
Weldon, nomination, Centers for Disease Control and Prevention (U.S.), Confirmation, Vaccines, Weldon ‘s, Senate
New Uplizna data drop in myasthenia gravis, while clock ticks on IgG4 decision
Uplizna, Myasthenia Gravis, Effectiveness, Improvement
Mallinckrodt and Endo Announce $6.7 Billion Merger to Create Diversified Pharmaceutical Leader
Pharmaceutical merger, Mallinckrodt, Endo, opioid litigation, generics, branded drugs, synergies
Corrected: Merck opens billion-dollar US facility to make Gardasil
Merck, Gardasil, Facility (object), Vaccines, Merck ‘s, United States
Roche expands obesity pipeline, paying Zealand Pharma $1.65B upfront to codevelop amylin asset
This deal represents a major expansion of Roche’s obesity drug pipeline and a significant partnership in the competitive weight loss medication market.
Viking Signs $150M Manufacturing Agreement with CordenPharma for Obesity Drug Candidate
Viking Therapeutics, CordenPharma, VK2735, obesity drug, manufacturing agreement, GLP-1/GIP dual agonist
Insilico secures $110M in new funding for AI-designed pipeline
Clinical Trials, Aortic Valve Insufficiency
Viking Therapeutics Signs $150 Million Manufacturing Deal with CordenPharma for Obesity Drug VK2735
Viking Therapeutics, CordenPharma, VK2735, Obesity drug, GLP-1/GIP dual agonist, Contract manufacturing, API production, Fill/finish capacity, Subcutaneous and oral formulations
Pharmaceutical Giants Mallinckrodt and Endo Explore $7 Billion Merger
Pharmaceutical merger, Mallinckrodt, Endo, $7 billion deal, Specialty pharmaceutical companies, Post-bankruptcy consolidation, Opioid crisis fallout
Ono Pharmaceutical Acquires Global Rights to Ionis’ Sapablursen for Polycythemia Vera in $940M Deal
Ono Pharmaceutical, Ionis Pharmaceuticals, sapablursen, polycythemia vera, licensing agreement, RNA-targeted medicine